Friday, 18 May 2012
  • LEGAL NOTICE
  • CONTACT US
  • SITEMAP

Axiogenesis-Logo

  • HOME
  • PRODUCTS
    • Product selection guide
    • Human Cardiomyocytes iPS
      • Cor.4U MEA
    • Murine Cardiomyocytes ES
      • CELLS
      • Cor.At GFP
      • Cor.At CL - Colorless
      • CUSTOMIZED FORMATS
      • Cor.At-X xCELLigence Cardio
      • KITS
      • Cor.At GFP Starter Kit
      • Cor.At RNA (Day 2 & Day 14)
      • Cor.At Cardiotoxicity Kit
    • Murine Cardiomyocytes iPS
      • Cor.At Colorless iPS
    • Murine Endothelial Cells
      • Endo.4M
    • Murine Smooth Muscle Cells
      • Smac.4M
  • SERVICES
    • Services selection guide
    • Electrophysiology Services
      • Human MEA (Cor.4U)
      • Mel.Cor MEA (Cor.At)
      • Cor.At CardioEffect Screening
    • Toxicology Services
      • µEST - Embryotoxicity
      • Cor.At Tox
      • E-Screen
      • ToxEffect screening
      • General cytotoxicity testing
    • Drug Development Services
      • My.Cor - Cardiomyopathy screen
    • Customized Services
  • APPLICATIONS
    • Application selection guide
    • Electrophysiology
      • Manual patch clamp
      • Automated patch clamp
      • MEA analysis
      • Calcium flux analysis/Fluo-4 FLIPR
    • Roche xCELLigence Cardio
      • Roche xCELLigence Cardio with Cor.At
    • Cardiotoxicity
      • Neutral Red Uptake
      • Troponin release
      • Label-free analysis
    • Mitochondrial toxicity
      • Oxygen consumption (MitoXpress®)
    • Drug profiling & target discovery
      • Hypertrophy
      • Gene expression
      • Transfection
  • SCIENCE & TECHNOLOGY
    • Stem cell technology
      • Embryonic stem cells
      • Induced pluripotent stem cells
    • Product technology
      • Drug discovery
    • Documentation
      • Publications
  • COMPANY
    • Meet us
    • News & Media
    • Overview / Profile
    • Management & Team
      • Executive Board
        • Statements
      • Advisory Board
      • Scientific Advisory Board
    • Investor Relations
    • Partners
    • Contact us
    • Login
Axiogenesis and Yamanaka (iPS Academia) sign
license agreement to generate
(iPS) derived HUMAN CARDIOMYOCYTES and other tissue
Important patent granted to Axiogenesis
in Europe and Japan
on the use of hypertrophic cardiac cells in drug development
  • Meet us
  • News & Media
  • Overview / Profile
  • Management & Team
    • Executive Board
      • Statements
    • Advisory Board
    • Scientific Advisory Board
  • Investor Relations
  • Partners
  • Contact us
  • Login

Login

Login
  • Forgot your Password?
  • Forgot your Username?

Copyright © 2011 AXIOGENESIS AG